Datapoint: Padcev Snags Expanded Approvals in Bladder Cancer

The FDA last week granted Seagen Inc. and Astellas Pharma’s Padcev two expanded bladder cancer indications, following a priority review. The antibody-drug conjugate now has regular approval as a third-line treatment for metastatic or locally advanced urothelial cancer, plus a new nod as a second-line therapy for bladder cancer patients who are ineligible for certain types of chemotherapy. For the treatment of bladder cancer, Padcev currently holds covered or better status for 54% of all insured lives under the pharmacy benefit. Under the medical benefit, Padcev is covered or better for 82% of lives.

SOURCE: MMIT Analytics, as of 7/14/

0

0

0 Comments

0

0

• Datapoint